Patents by Inventor Nuria A. Tamayo
Nuria A. Tamayo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101570Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).Type: ApplicationFiled: November 22, 2021Publication date: March 28, 2024Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Francesco MANONI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Nuria A. TAMAYO, Mikkel VESTERGAARD, Hui-Ling WANG, Nicholas Anthony WEIRES
-
Publication number: 20240092794Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: ApplicationFiled: November 6, 2023Publication date: March 21, 2024Applicant: AMGEN INC.Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
-
Publication number: 20240059703Abstract: Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.Type: ApplicationFiled: October 19, 2021Publication date: February 22, 2024Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, JOSEPHINE ESHON, DAVID HUANG, MATTHEW R. KALLER, HEEJUN LEE, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M MEDINA, ALEXANDER J. PICKRELL, JOHN C. STELLWAGEN, ZHEN SUN, NURIA A. TAMAYO, WENHAN ZHANG, KAI ZHU
-
Patent number: 11905281Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: September 24, 2020Date of Patent: February 20, 2024Assignee: Amgen Inc.Inventors: Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen
-
Publication number: 20240050430Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 23, 2023Publication date: February 15, 2024Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Publication number: 20230406860Abstract: The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.Type: ApplicationFiled: October 26, 2021Publication date: December 21, 2023Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
-
Patent number: 11845760Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: GrantFiled: December 15, 2021Date of Patent: December 19, 2023Assignee: AMGEN INC.Inventors: Shon Booker, Matthew Paul Bourbeau, John R. Butler, Sanne Ormholt Schroder Glad, Brian Alan Lanman, Patricia Lopez, Francesco Manoni, Liping H. Pettus, Ian Sarvary, Nuria A. Tamayo, Mikkel Vestergaard, Nicholas Anthony Weires
-
Patent number: 11766436Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 30, 2021Date of Patent: September 26, 2023Assignee: Amgen Inc.Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Publication number: 20230159510Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: ApplicationFiled: February 11, 2021Publication date: May 25, 2023Applicant: AMGEN INC.Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
-
Publication number: 20220395504Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 30, 2021Publication date: December 15, 2022Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Publication number: 20220372018Abstract: Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: August 3, 2020Publication date: November 24, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Richard KALLER, Thomas T. NGUYEN, Nobuko NISHIMURA, Qiufen May XUE, John Gordon ALLEN, Michael J. FROHN
-
Publication number: 20220289724Abstract: Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.Type: ApplicationFiled: August 3, 2020Publication date: September 15, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Paul BOURBEAU, Matthew Richard KALLER, Jonathan Dante LOW, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Liping H. PETTUS, Mary Catherine WALTON, Qiufen May XUE, John Gordon ALLEN
-
Publication number: 20220281843Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: August 3, 2020Publication date: September 8, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Matthew Paul BOURBEAU
-
Publication number: 20220194955Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: ApplicationFiled: December 15, 2021Publication date: June 23, 2022Applicant: AMGEN INC.Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
-
Publication number: 20220175782Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: January 19, 2022Publication date: June 9, 2022Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
-
Publication number: 20220106293Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 14, 2021Publication date: April 7, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
-
Patent number: 11285156Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 11, 2019Date of Patent: March 29, 2022Assignee: AMGEN INC.Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
-
Publication number: 20220073504Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 20, 2019Publication date: March 10, 2022Applicant: AMGEN INC.Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JAMES ALEXANDER BROWN, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, QINGYIAN LIU, JONATHAN DANTE LOW, VU MA, LIPING H PETTUS, MARY CATHERINE WALTON, ANA ELENA MINATTI, MATTHEW PAUL BOURBEAU, LEI JIA, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
-
Publication number: 20220056015Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 20, 2019Publication date: February 24, 2022Applicant: AMGEN INC.Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JIAN JEFFREY CHEN, KEXUE LI, LIPING H. PETTUS, MATTHEW PAUL BOURBEAU, LEI JIA
-
Patent number: 11236069Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: GrantFiled: December 20, 2019Date of Patent: February 1, 2022Assignee: AMGEN INC.Inventors: Nuria A. Tamayo, Abhisek Banerjee, Jian Jeffrey Chen, Jonathan Dante Low, Ana Elena Minatti, Matthew Paul Bourbeau